不同化疗方案同步调强放疗治疗Ⅲ～Ⅳ a期鼻咽癌疗效的回顾性分析

吴峰; 吴立连; 陈国富; 黄玉婵

doi:10.13201/j.issn.1001-1781.2016.19.008

不同化疗方案同步调强放疗治疗Ⅲ～Ⅳ a期鼻咽癌疗效的回顾性分析

- 1. 湖北科技学院附属第二医院耳鼻咽喉科(湖北咸宁, 437100);
- 2. 江苏省泰州职业技术学院医学技术学院;
- 3. 湖北科技学院五官医学院

详细信息

通讯作者: 黄玉婵,E-mail:wufengwff@163.com

中图分类号: R739.63

收稿日期: 2016-06-22

Retrospective study on the efficacy of different chemotherapy regimens concurrently combined with intensity modulated radiation therapy in treatment of Ⅲ-Ⅳ a stage nasopharyngeal carcinoma

- 1. Department of Otolaryngology, the Second Hospital Affiliated to Hubei University of Science and Technology, Xianning, 437100, China;
- 2. Department of Medical Institute of Technology, Taizhou Polytechnic College;
- 3. Five senses Medical College, Hubei Science and Technology College

More Information

Corresponding author: HUANG Yuchan, E-mail: wufengwff@163.com

Received Date: 22 June 2016

摘要

摘要: 目的:比较紫杉醇(TAX)联合顺铂(DDP)(TP方案)与DDP联合5-氟尿嘧啶(PF方案)同步调强放疗(IMRT)治疗Ⅲ~Ⅳa期鼻咽癌(NPC)的近远期临床疗效与安全性。方法:回顾性分析108例晚期NPC患者资料,根据治疗方案分为TP组与PF组,TP组予IMRT放疗同步TP化疗方案,PF组予IMRT放疗同步PF化疗方案,两组均采用4周期化疗方案,同步放化疗中记录毒性反应,治疗结束后2个月判定近期疗效,治疗结束后随访3年,记录随访期间肿瘤复发率、转移率、局部控制率与生存率。结果:治疗结束后TP组总有效率(84.2%)高于PF组(76.5%),差异无统计学意义(P>0.05)。两组放化疗期间胃肠道反应(70.2%vs.66.7%)、骨髓抑制(75.4% vs.82.4%)、听力损害(15.8% vs.15.7%)、肝功能损害(12.3% vs.13.7%)、放射性口咽部损伤(91.2% vs.98.0%)发生率无明显差异(P>0.05)。随访期间,TP组复发转移率(33.3%)低于PF组(47.1%) (χ²=2.116,P=0.146)。TP组治疗结束后3年局部控制率(73.7% vs.68.5%)、生存率(84.2% vs.78.4%)均高于PF组(χ²=0.336,P=0.562;χ²=0.596,P=0.440)。结论:IMRT同步TP与PF方案均是治疗晚期NPC的有效方案,IMRT同步TP方案在近远期临床疗效与毒性反应方面比较具有优势。
- 鼻咽肿瘤 /
- 调强放疗 /
- 毒性反应 /
- 生存率
Abstract: Objective:To compare the near and long term efficacy and safety of paclitaxel(TAX) plus cisplatin(DDP) (TP regimen) and DDP plus 5-FU(PF regimen) concurrently combined with IMRT in treatment of patients with advanced NPC.Method:A retrospective analysis on 108 advanced NPC cases from January 2010 to December 2012 was conducted. The patients were divided into TP group(57 cases) and PF group(51 cases) according to therapy regimen. TP group received IMRT combined with TP therapy, and PF group received IMRT combined with PF regimen, two groups were both used 4 cycles of chemotherapy, toxicity reactions during concurrent radiochemotherapy were noted. Two months after treatment, near clinical efficacies of the two groups were determined, and then, a three years following-up was conducted, during which recurrence ratio, metastasis ratio, local control ratio and survival rate were analyzed.Result:Two months after treatment, the total effective ratio of TP group(84.2% vs.76.5%) was higher than PF group,however, the difference was not statistically significant(P>0.05). Gastrointestinal reaction(70.2% vs.66.7%), marrow inhibition(75.4% vs.82.4%), liver function damage(12.3% vs.13.7%), radioactive oral&pharyngeal injury(91.2% vs.98.0%), hearing damage(15.8% vs.15.7%) in the two groups during chemoradiotherapy had no significant differences(P>0.05). During following-up, the recurrence &metastasis ratio in TP group(33.3% vs.47.1%) was lower than PF group(χ²=2.116,P=0.146). TP group with The local control rate(73.7% vs.68.5%) and survival rate(84.2% vs.78.4%) after three years treatment in TP group were higher than PF group(χ²=0.336,P=0.562;χ²=0.596,P=0.440).Conclusion:IMRT concurrently combined with TP and PF respectively are both effective methods for treatment of advanced NPC. In this study, IMPT plus TP concurrent chemoradiotherapy has a certain superiority in near and long term clinical treatment efficacy and safety.
- nasopharyngeal neoplasms /
- intensity modulated radiation therapy /
- toxicity /
- survival rate

HTML全文

参考文献(15)

[1]	LEE A W,MA B B,NG W T,et al.Management of Nasopharyngeal Carcinoma:Current Practice and Future Perspective[J].J Clin Oncol,2015,33:3356-3364.
[2]	魏锐文,范敏.调强放疗联合不同化疗方案治疗NPC的疗效比较[J].四川医学,2015,36(12):1654-1656.
[3]	HERMAN L C,CHEN L,GARNETT A,et al.Comparison of carboplatin-paclitaxel to docetaxel-cisplatin-5-flurouracil induction chemotherapy followed by concurrent chemoradiation for locally advanced head and neck cancer[J].Oral Oncol,2014,50:52-58.
[4]	DONG Y Y,XIANG C,LU J X,et al.Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrentchemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma:Amatched-pair multicenter analysis of outcomes[J].Strahlenther Onkol,2016,192:394-402.
[5]	迟峰,肖玉平,曾越灿,等.TP方案与PF方案化疗同步放疗对局部晚期喉癌的效果观察[J].临床误诊误治,2014,27(9):25-27.
[6]	DU X J,TANG L L,CHEN L,et al.Neoadjuvant chemotherapy in locally advanced nasopharyngeal carcinoma:Defining high-risk patients who may benefit before concurrent chemotherapycombined with intensity-modulated radiotherapy[J].Sci Rep,2015,5:16664.
[7]	KONG F,CAI B Z,CHEN X Z,et al.Prognostic factors for survival of patients with nasopharyngeal carcinoma following conventional fractionation radiotherapy[J].Exp Ther Med,2013,6:57-60.
[8]	HWANG C F,FANG F M,ZHUO M Y,et al.Hearing Assessment after Treatment of Nasopharyngeal Carcinoma with CRT and IMRT Techniques[J].Biomed Res Int,2015,2015:769806.
[9]	胡丹,熊俊.鼻咽癌常规放疗与调强放疗远期并发症及疗效的对比分析[J].实用癌症杂志,2014,29(6):716-718.
[10]	PERRI F,DELLA VITTORIA SCARPATI G,BUONERBA C,et al.Combined chemo-radiotherapy in locally advanced nasopharyngeal carcinomas[J].World J Clin Oncol,2013,4:47-51.
[11]	CHEN Y P,GUO R,LIU N,et al.Efficacy of the Additional Neoadjuvant Chemotherapy to Concurrent Chemoradiotherapy for Patients with Locoregionally Advanced Nasopharyngeal carcinoma:a Bayesian Network Meta-analysis of Randomized Controlled Trials[J].J Cancer,2015,6:883-892.
[12]	曹爽,吴宇,王卉,等.局部晚期NPC洛铂单药与PF方案同步放化疗临床观察[J].临床与病理杂志,2015,35(9):1668-1670.
[13]	SU Z,MAO Y P,TANG J,et al.Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stageⅡnasopharyngeal carcinoma treated with IMRT:a retrospective study[J].Tumour Biol,2016,37:4429-4438.
[14]	胡佳.47例紫杉醇注射液过敏反应文献分析[J].中国药业,2012,21(6):53-54.
[15]	汤晨,郁汉旭,刘收厚,等.紫杉醇加顺铂方案与顺铂加氟尿嘧啶方案化疗同步放疗对局部晚期喉癌的效果和毒性[J].中国煤炭工业医学杂志,2015,18(9):1460-1462.